ACADIA Pharmaceuticals (FRA:DR6) Cyclically Adjusted FCF per Share: €-0.64 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
79 GF Score
Price €24.73
GF Value €21.63
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share?

ACADIA Pharmaceuticals FRA:DR6 +0.08% 79 Cyclically Adjusted FCF per Share is €-0.64 as of Jun. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 79/100 and a GF Value™ of €21.63 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was €0.481. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.64 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 2.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ACADIA Pharmaceuticals was 13.60% per year. The lowest was -8.70% per year. And the median was -1.40% per year.

As of today (2026-09-02), ACADIA Pharmaceuticals's current stock price is €24.73. ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.64. ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


ACADIA Pharmaceuticals  (FRA:DR6) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.06 -1.19 -1.13 -0.97 -0.68

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.92 -0.68 -0.71 -0.64

FRA:DR6 vs PBLS, DYN, EWTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:DR6
79GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.481/333.9520*333.9520
=0.481

Current CPI (Jun. 2026) = 333.9520.

ACADIA Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.377 241.428 -0.521
201612 -0.480 241.432 -0.664
201703 -0.546 243.801 -0.748
201706 -0.431 244.955 -0.588
201709 -0.400 246.819 -0.541
201712 -0.204 246.524 -0.276
201803 -0.297 249.554 -0.397
201806 -0.281 251.989 -0.372
201809 -0.297 252.439 -0.393
201812 -0.264 251.233 -0.351
201903 -0.400 254.202 -0.525
201906 -0.236 256.143 -0.308
201909 -0.118 256.759 -0.153
201912 -0.174 256.974 -0.226
202003 -0.291 258.115 -0.376
202006 -0.226 257.797 -0.293
202009 -0.132 260.280 -0.169
202012 -0.152 260.474 -0.195
202103 -0.321 264.877 -0.405
202106 -0.131 271.696 -0.161
202109 -0.090 274.310 -0.110
202112 -0.126 278.802 -0.151
202203 -0.430 287.504 -0.499
202206 -0.077 296.311 -0.087
202209 -0.005 296.808 -0.006
202212 -0.139 296.797 -0.156
202303 -0.103 301.836 -0.114
202306 0.046 305.109 0.050
202309 -0.336 307.789 -0.365
202312 0.475 306.746 0.517
202403 0.161 312.332 0.172
202406 0.140 314.175 0.149
202409 0.343 315.301 0.363
202412 0.231 315.605 0.244
202503 -0.433 319.799 -0.452
202506 0.835 322.561 0.864
202509 -0.125 324.800 -0.129
202512 0.229 324.054 0.236
202603 0.144 330.213 0.146
202606 0.481 333.952 0.481

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.64 mean?
ACADIA Pharmaceuticals (FRA:DR6) has a Cyclically Adjusted FCF per Share of €-0.64 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
ACADIA Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-0.64. Overall, ACADIA Pharmaceuticals has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Cyclically Adjusted FCF per Share compare to PBLS and DYN?
ACADIA Pharmaceuticals' Cyclically Adjusted FCF per Share of €-0.64 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.63, compared to a current price of €24.73 — trading 14.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.64. ACADIA Pharmaceuticals' overall GF Score™ is 79/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Cyclically Adjusted FCF per Share is €-0.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of €24.73 is trading 14.3% above its estimated GF Value™ of €21.63. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for FRA:DR6:

  • Cyclically Adjusted FCF per Share: €-0.64
  • GF Value™: €21.63 vs. price of €24.73 (14.3% above fair value)
  • GF Score™: 79/100 with 10 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
79GF Score

Get the complete analysis for FRA:DR6

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.73
Price
€21.63
GF Value